Small Stocks, Big Money™

OS Therapies (NYSE American: OSTX) successfully administered the final treatment dose in its Phase 2b clinical trial of OST-HER2 for recurrent osteosarcoma. With all 41 patients now fully treated, the company will close clinical sites and prepare for data analysis, with topline results expected in Q4 2024. This milestone marks a significant step in the development of OST-HER2, a promising immunotherapy aimed at preventing metastasis and improving survival in osteosarcoma patients, a field where no new treatments have been approved in over 40 years.

Zomedica Corp. (NYSE American: ZOM) announced that its Assisi Loop® product line has been reaffirmed as a Fear Free™ Preferred Product, aligning with Fear Free’s mission to alleviate fear, anxiety, and stress in pets. The Assisi Loop® uses targeted pulsed electromagnetic field (tPEMF) technology to reduce pain, inflammation, and canine anxiety. Larry Heaton CEO of Zomedica, stated, "Veterinarians seeking effective therapeutic solutions that minimize pain and anxiety in pets naturally turn to the Assisi suite of products. The gentle signals generated by the proprietary technology, which can be utilized from the comfort of home, align perfectly with the increasing demand for non-invasive veterinary care.”

BioVie (Nasdaq: BIVI) presented compelling clinical data at the 11th Aging Research and Drug Discovery Meeting, revealing that its drug candidate, Bezisterim, may significantly modulate inflammation and decelerate biological aging. Patients treated with Bezisterim experienced a 2 to 4-year age deceleration advantage compared to placebo, alongside a transition from proinflammatory to anti-inflammatory macrophage states. The data also highlighted Bezisterim's potential to impact gene pathways related to neurodegenerative disorders like Alzheimer’s and Parkinson’s, positioning it as a promising therapeutic candidate in the fight against age-related diseases.

OKYO Pharma (Nasdaq: OKYO) was granted a U.S. patent for its innovative drug candidate, OK-101, which targets symptoms of dry eye disease (DED) such as irritation, burning, and blurred vision. This patent strengthens OKYO’s intellectual property portfolio and supports its ongoing efforts to address significant unmet needs in ocular health. OK-101, a long-acting chemerin peptide agonist, has demonstrated promising anti-inflammatory and pain-reducing effects in preclinical and clinical studies, positioning it as a potential game-changer in the multi-billion-dollar DED market.